[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
$23share
Avadel Pharmaceuticals is considering an unsolicited acquisition offer of up to $23/share from H. Lundbeck, which includes cash and potential milestone payments. The board believes the offer could be a superior proposal.
About $23share
$23share refers to a potential acquisition price per share for Avadel Pharmaceuticals.
Insights
- $23share creators is up XX% from the previous week.
- $23share engagements is up 1118.66% from the previous month.
- $23share mentions is up XXX% from the previous week.
Engagements: XX (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: XX
Daily Average: XXXXX
X Week: XXX +57%
X Month: XXXXXX +1,119%
X Months: XXXXXXX +55%
X Year: XXXXXXX -XX%
1-Year High: XXXXXX on 2025-02-03
1-Year Low: X on 2024-12-28
Engagements by network (24h): X: XX
Mentions: X (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: X
Daily Average: X
X Week: XX +120%
X Month: XX +13%
X Months: XXX +349%
X Year: XXX +107%
1-Year High: XX on 2025-08-19
1-Year Low: X on 2024-12-12
Mentions by network (24h): X: X
Creators: X (24h)
Creators 24-Hour Time-Series Raw Data
X unique social accounts have posts mentioning $23share in the last XX hours which is down XX% from X in the previous XX hours
Daily Average: X
X Week: X +80%
X Month: XX +64%
X Months: XXX +257%
X Year: XXX +71%
1-Year High: XX on 2025-08-19
1-Year Low: X on 2024-12-12
The most influential creators that mention $23share in the last XX hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @InsideArbitrage | X | XXXXX | X | XX |
Top $23share Social Posts
Top posts by engagements in the last XX hours
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"Avadel Pharmaceuticals $AVDL announced it received an unsolicited acquisition proposal from H. Lundbeck for up to $23/share. The offer includes $XX in cash plus $X in CVR tied to future LUMRYZ and valiloxybate U.S. net sales milestones ($1 if they reach $450M by 2027 and another $X if they reach $700M by 2030). Avadels Board says the offer would reasonably be expected to qualify as a Company Superior Proposal but theres no assurance discussions will lead to a final determination or a deal"
X Link @InsideArbitrage 2025-11-14T11:29Z 5627 followers, 3130 engagements